Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer
Authors:
- 1 January 2019
- journal article
- research article
- Vol. 12 (3) , 957-967
Abstract
The mutation of Kirsten rat sarcoma viral oncogene homolog (KRAS) has been reported to be prognostically important in patients with colorectal cancer (CRC). In this study, we investigated whether all KRAS mutations predict poor prognosis in patients with CRC. Our analysis of characteristics of KRAS mutations revealed the mutation rate for codon 12 was 72.7%, of which G12D was the highest (47.5%) followed by G12V (30.6%), and the mutation rate for codon 13 was 22.0%, of which all were G13D. In support of the concept that prognostic value of the KRAS codon-12 mutations is different from the codon-13 mutations, results from our Cox proportional hazard model studies showed that codon-12 mutations correlated with worse overall survival (OS; HR = 2.846, 95% CI: 1.967-4.118, P < 0.001) and progression free survival (PFS; HR = 2.011, 95% CI: 1.450-2.789, P < 0.001). No prognostic significance was revealed for codon-13 mutations. On further analysis, we found that mortality risk was significantly increased with G12D and G12V (G12D: HR = 2.802, 95% CI: 1.793-4.381, P < 0.001; G12V: HR = 2.802, 95% CI: 1.793-4.381, P < 0.001), as was the risk of disease progression (G12D: HR = 2.079, 95% CI: 1.396-3.099, P < 0.001; G12V: HR = 2.408, 95% CI: 1.517-3.822, P < 0.001). To conclude, our results support the concept that codon-12 mutations were predictive for a poor prognosis in Chinese patients with CRC. Specifically, G12D and G12V were independent prognostic factors for worse OS and PFS.Keywords
This publication has 29 references indexed in Scilit:
- Prognostic value ofKRASandBRAFmutations in curatively resected colorectal cancerWorld Journal of Gastroenterology, 2015
- Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to PanitumumabJournal of Clinical Oncology, 2013
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsAnnals of Oncology, 2010
- Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosisInternational Journal of Cancer, 2009
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort StudyCarcinogenesis, 2003
- K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.2000
- Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggressionThe Journal of Pathology, 1999
- Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" StudyJNCI: Journal of the National Cancer Institute, 1998
- Ras signalling and apoptosisCurrent Opinion in Genetics & Development, 1998